-transparent.png){kind=logo}
The effect of treatment for eight weeks with isradipine 1.25 mg twice daily for 4 weeks and thereafter 2.5 mg twice daily for 4 weeks on ex vivo platelet function was investigated in 10 male hypertensive patients, aged 51 (6.1) y. Systolic and diastolic blood pressure, platelet aggregation in response to ADP, serum thromboxane B2 and beta-thromboglobulin levels were significantly decreased at rest before exercise ergometry, during exercise and at rest after exercise. The platelet count, platelet sensitivity and the plasma levels of 6-oxo-prostaglandin F1 alpha were not affected by isradipine. It is concluded that a compound that lowers blood pressure and inhibits platelet activation may be of clinical benefit in the routine treatment of hypertension.
H Sinzinger, and
I Virgolini, and
F Rauscha, and
P Fitscha, and
J O'Grady
May 1996,
Cardiovascular drugs and therapy,
H Sinzinger, and
I Virgolini, and
F Rauscha, and
P Fitscha, and
J O'Grady
June 1997,
Thrombosis research,
H Sinzinger, and
I Virgolini, and
F Rauscha, and
P Fitscha, and
J O'Grady
November 1989,
Archives of internal medicine,
H Sinzinger, and
I Virgolini, and
F Rauscha, and
P Fitscha, and
J O'Grady
July 2003,
Prostaglandins, leukotrienes, and essential fatty acids,
H Sinzinger, and
I Virgolini, and
F Rauscha, and
P Fitscha, and
J O'Grady
January 2006,
Heart (British Cardiac Society),
H Sinzinger, and
I Virgolini, and
F Rauscha, and
P Fitscha, and
J O'Grady
November 2003,
Vox sanguinis,
H Sinzinger, and
I Virgolini, and
F Rauscha, and
P Fitscha, and
J O'Grady
January 1983,
Hypertension (Dallas, Tex. : 1979),
H Sinzinger, and
I Virgolini, and
F Rauscha, and
P Fitscha, and
J O'Grady
January 1991,
Journal of cardiovascular pharmacology,
H Sinzinger, and
I Virgolini, and
F Rauscha, and
P Fitscha, and
J O'Grady
May 1989,
Thrombosis research,
H Sinzinger, and
I Virgolini, and
F Rauscha, and
P Fitscha, and
J O'Grady
August 1999,
Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
